系统性PCSK9升高的特征是跨性别的自身免疫性肝病
Patricia Mester1, Vlad Pavel1, Petra Stoeckert1
1Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, Immunology, and Infectious Diseases, University Hospital Regensburg, 93053, Regensburg, Germany.
Scientific reports
|November 21, 2025
概括
在患有自身免疫性肝病的患者中,血清PCSK9水平升高,显示出作为诊断生物标志物的潜力. 无论胆固醇或纤维化,这些升高的水平都被观察到,即使通过正常的肝功能测试,也有助于诊断.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 免疫学 免疫学 免疫学
- 生物化学 生物化学
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 调节血清胆固醇,在肝细胞中大量存在.
- 在自身免疫性肝病 (AILD) 中PCSK9的作用尚不清楚.
- 在AILD中研究PCSK9对于了解疾病机制和潜在的生物标志物至关重要.
研究的目的:
- 与健康对照组相比,研究AILD患者的血清PCSK9水平.
- 在AILD亚型中探索PCSK9水平的性别特异性差异.
- 为了评估PCSK9对AILD的诊断性能.
主要方法:
- 在100名AILD患者 (PSC,PBC,AIH) 和88名健康对照人群中测量了血清PCSK9水平.
- 根据性别和疾病类型进行了子组分析.
- 用接收器操作特征 (ROC) 曲线来评估诊断性能.
主要成果:
- 与对照组相比,AILD患者的PCSK9水平显著升高 (p < 0.001).
- 观察到性别特异性歧视:男性的PCSK9差异化PSC和女性的PBC (分别为AUROC0.765±0.057和0.834±0.047).
- PCSK9确定了AILD患者的肝功能测试正常 (AUROC 0.788 ± 0.039),其中224ng/ml显示92%的灵敏度和60%的特异性.
结论:
- 在男性和女性AILD患者中,血清PCSK9水平升高.
- PCSK9可以作为诊断AILD的宝贵生物标志物,即使在近乎正常的肝功能测试的情况下也是如此.
- PCSK9水平与胆固醇,疾病严重程度或纤维化阶段没有相关性.
更多相关视频
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K
Nephrotic Syndrome I : Introduction
476
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
476
Hepatic Drug Clearance: Effect of Protein Binding
505
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
505


